標(biāo)題: Titlebook: Cardiac Extracellular Matrix; Fundamental Science Eric G. Schmuck,Peiman Hematti,Amish N. Raval Book 2018 Springer Nature Switzerland AG 2 [打印本頁] 作者: 去是公開 時(shí)間: 2025-3-21 16:07
書目名稱Cardiac Extracellular Matrix影響因子(影響力)
作者: PIZZA 時(shí)間: 2025-3-21 20:13
Proofs, New Results and Technical Details,sources of natural ECMs have been tested for cardiac applications. Typically, natural ECMs have been made from decellularized organs or tissues and processed into either sheets or injectable hydrogels. This chapter will review natural sources of ECM materials that have been tested as therapeutic agents in models of heart failure.作者: Anhydrous 時(shí)間: 2025-3-22 03:16 作者: NIP 時(shí)間: 2025-3-22 06:37
Natural Sources of Extracellular Matrix for Cardiac Repair,sources of natural ECMs have been tested for cardiac applications. Typically, natural ECMs have been made from decellularized organs or tissues and processed into either sheets or injectable hydrogels. This chapter will review natural sources of ECM materials that have been tested as therapeutic agents in models of heart failure.作者: 有偏見 時(shí)間: 2025-3-22 09:22 作者: 平躺 時(shí)間: 2025-3-22 16:55
Book 2018Applications.. In the Fundamental Science section, we will cover the spectrum of basic ECM science from ECM’s role in development, biomechanical properties, cardiac ECM influence of cardiomyocyte biology, pathophysiology of ECM in heart disease, and ECM in tissue engineering. Section two, Preclinica作者: 平躺 時(shí)間: 2025-3-22 20:43
On the Mean Residual Life Regression Model,nents of biologic scaffolds composed of ECM, the mechanisms by which ECM bioscaffolds promote constructive cardiac remodeling after injury, determinants of remodeling outcome, and the versatility of ECM as a potential cardiac therapeutic.作者: QUAIL 時(shí)間: 2025-3-22 22:14 作者: Melanocytes 時(shí)間: 2025-3-23 04:53 作者: 搖擺 時(shí)間: 2025-3-23 06:51 作者: Iatrogenic 時(shí)間: 2025-3-23 11:50
Yu. I. Ingster,Irina A. Suslinatrials are underway to characterize the role of C-ECM and demonstrate efficacy for acute and chronic heart disease. This chapter reviews animal models used to enhance our knowledge of C-ECMs in heart disease and its use in the treatment of heart disease.作者: MAUVE 時(shí)間: 2025-3-23 17:55
https://doi.org/10.1007/0-387-29053-2across all biologic treatment options. Future progress in this field may include testing combinations of cells, gene-transfer agents, and matrix and identifying treatment responders versus nonresponders.作者: 無表情 時(shí)間: 2025-3-23 18:59
Animal Models and Cardiac Extracellular Matrix Research,trials are underway to characterize the role of C-ECM and demonstrate efficacy for acute and chronic heart disease. This chapter reviews animal models used to enhance our knowledge of C-ECMs in heart disease and its use in the treatment of heart disease.作者: 織布機(jī) 時(shí)間: 2025-3-23 22:31 作者: Jejune 時(shí)間: 2025-3-24 02:22 作者: conservative 時(shí)間: 2025-3-24 07:55 作者: BIDE 時(shí)間: 2025-3-24 14:00 作者: 或者發(fā)神韻 時(shí)間: 2025-3-24 15:16
Nonparametric Density Estimation,pment has become increasingly apparent. These signals have been shown to influence many fundamental cardiac cell behaviors including contractility, proliferation, migration, and differentiation. Consequently, alterations to cell phenotype result in directed remodeling of the cECM. This bidirectional作者: CLOT 時(shí)間: 2025-3-24 19:17
https://doi.org/10.1007/978-3-319-71688-6-free extracellular matrix (ECM) that can be used as a cardiac tissue bioscaffold. The field of whole-heart tissue engineering has been revolutionized since the 2008 publication of the first perfusion-decellularized whole heart, and since then, studies have shown how decellularized cardiac tissue re作者: 賞心悅目 時(shí)間: 2025-3-25 02:04
Proofs, New Results and Technical Details,gent. To this end, many ECMs have been investigated for cardiac tissue engineering and regenerative medicine applications with variable success. Many sources of natural ECMs have been tested for cardiac applications. Typically, natural ECMs have been made from decellularized organs or tissues and pr作者: 混合 時(shí)間: 2025-3-25 07:17
Proofs, New Results and Technical Details,hemical support to cardiovascular tissue. The roles of cECM proteins and the associated family of cell surface receptor, integrins, have been explored in vivo via the generation of knockout experimental animal models. However, the complexity of tissues makes it difficult to isolate the effects of in作者: bisphosphonate 時(shí)間: 2025-3-25 08:48 作者: 放氣 時(shí)間: 2025-3-25 12:41 作者: escalate 時(shí)間: 2025-3-25 17:45 作者: 媽媽不開心 時(shí)間: 2025-3-25 21:25
https://doi.org/10.1007/0-387-29053-2vascular disease. A well-constructed clinical trial design for these novel therapies requires careful attention to defining a clear hypothesis, a patient population, and anticipated outcomes. The scope of screening, method of randomization, blinding approach, data monitoring, and statistical analysi作者: GEM 時(shí)間: 2025-3-26 01:00
On the Mean Residual Life Regression Model, uncertainty have slowed market entry of regenerative medicine treatments. As a result, commercial development has often been led by entrepreneurial ventures rather than large biopharma firms. Translating regenerative medicine across the university-industry boundary links academic scientists, techno作者: 踉蹌 時(shí)間: 2025-3-26 05:48
Cardiac Extracellular Matrix978-3-319-97421-7Series ISSN 0065-2598 Series E-ISSN 2214-8019 作者: 出生 時(shí)間: 2025-3-26 08:53
Eric G. Schmuck,Peiman Hematti,Amish N. RavalComprehensively discusses recent discoveries in the field.Presents novel experimental approaches to developing potential therapies, including implications for Regenerative Medicine.Section on Clinical作者: Deference 時(shí)間: 2025-3-26 14:45
Advances in Experimental Medicine and Biologyhttp://image.papertrans.cn/c/image/221772.jpg作者: lambaste 時(shí)間: 2025-3-26 18:29
https://doi.org/10.1007/978-3-319-97421-7developmental biology; cardiac medicine; heart disease; cellular therapies; cardiac scar tissue作者: Irascible 時(shí)間: 2025-3-26 22:04
978-3-030-07353-4Springer Nature Switzerland AG 2018作者: prick-test 時(shí)間: 2025-3-27 02:46 作者: 一回合 時(shí)間: 2025-3-27 08:00 作者: 拋射物 時(shí)間: 2025-3-27 11:24 作者: 刺激 時(shí)間: 2025-3-27 17:13 作者: 船員 時(shí)間: 2025-3-27 20:02 作者: 放牧 時(shí)間: 2025-3-28 01:51
Natural Sources of Extracellular Matrix for Cardiac Repair,gent. To this end, many ECMs have been investigated for cardiac tissue engineering and regenerative medicine applications with variable success. Many sources of natural ECMs have been tested for cardiac applications. Typically, natural ECMs have been made from decellularized organs or tissues and pr作者: JUST 時(shí)間: 2025-3-28 05:14
Cardiac Extracellular Matrix Modification as a Therapeutic Approach,hemical support to cardiovascular tissue. The roles of cECM proteins and the associated family of cell surface receptor, integrins, have been explored in vivo via the generation of knockout experimental animal models. However, the complexity of tissues makes it difficult to isolate the effects of in作者: watertight, 時(shí)間: 2025-3-28 09:39
Extracellular Matrix for Myocardial Repair,s or chemokines, stem/progenitor cell therapy, mechanical circulatory support, pharmacologic use, and the use of inductive biomaterials. The use of xenogeneic biologic scaffolds composed of extracellular matrix (ECM) has been shown to facilitate functional restoration of several tissues and organs i作者: lethargy 時(shí)間: 2025-3-28 11:01 作者: catagen 時(shí)間: 2025-3-28 17:53
Regulation of Regenerative Medicine Products, treat leukemia and other cell types to restore structure and function to tissues that have been damaged by disease or physical injury. The pace at which these treatments have evolved has posed a regulatory challenge to agencies, such as the Food and Drug Administration (FDA). This chapter describes作者: nurture 時(shí)間: 2025-3-28 20:17 作者: 委屈 時(shí)間: 2025-3-29 02:14
Regenerative Medicine Venturing at the University-Industry Boundary: Implications for Institutions, uncertainty have slowed market entry of regenerative medicine treatments. As a result, commercial development has often been led by entrepreneurial ventures rather than large biopharma firms. Translating regenerative medicine across the university-industry boundary links academic scientists, techno作者: 抱負(fù) 時(shí)間: 2025-3-29 04:28
Book 2018 scar tissue in the heart, Clinical trial design and regulatory considerations, current human clinical trials in cardiovascular medicine and the role of pharmaceutical and biotech companies in the commercialization of ECM technologies for cardiovascular indications. This book provides a comprehensiv作者: Mettle 時(shí)間: 2025-3-29 07:27
https://doi.org/10.1007/978-94-009-8117-1ew the mechanobiology of cardiac tissues, i.e., the biomechanical responses at the cellular and tissue level, with an emphasis on the impact on the cardiac ECM. The regulation of cardiac ECM on cell function, which is a new and open area of research, is also briefly discussed. Future investigation i作者: outrage 時(shí)間: 2025-3-29 15:13 作者: 柱廊 時(shí)間: 2025-3-29 18:03
Nonparametric Density Estimation,ardiac regeneration as well as bottom-up and top-down approaches to ECM-based cardiac tissue engineering is discussed. Finally, lingering questions regarding the role of cECM in tissue engineering and regenerative medicine are offered as a catalyst for future research.作者: ANTH 時(shí)間: 2025-3-29 22:59
https://doi.org/10.1007/978-3-319-71688-6he vascular conduits, injection into parenchyma, or a combination of perfusion and injection. Endothelial cells are often perfused through existing vessel conduits to provide an endothelial lining of the vasculature, with cardiomyocytes and other parenchymal cells injected into the myocardium of dec作者: Negotiate 時(shí)間: 2025-3-30 01:31
Proofs, New Results and Technical Details, fragments, and ECM mimics. Most recently 3D model systems have emerged, made possible by several developing technologies including, and most notably, 3D bioprinting. This chapter will attempt to track the evolution of our understanding of the relationship between cECM and cell behavior from in vivo作者: gusher 時(shí)間: 2025-3-30 05:22
Homegeneity Testing for Covariance Matrices,planted cells could restore the functionality and original composition of damaged ECM by secreting and depositing new ECM or stimulating normal ECM production by cardiac tissue native cells. Although the ultimate role of cell therapy in treatment of cardiac disorders is still a matter of great debat作者: 不能平靜 時(shí)間: 2025-3-30 08:24
Biomechanical Properties and Mechanobiology of Cardiac ECM,ew the mechanobiology of cardiac tissues, i.e., the biomechanical responses at the cellular and tissue level, with an emphasis on the impact on the cardiac ECM. The regulation of cardiac ECM on cell function, which is a new and open area of research, is also briefly discussed. Future investigation i作者: 紡織品 時(shí)間: 2025-3-30 14:06
Imaging the Cardiac Extracellular Matrix,le noninvasive methods and cellular-scale invasive methods. Noninvasive methods can be used on patients, but only a few are clinically available, and others require further development to be used in the clinic. Invasive methods are the most established and can measure a variety of properties, but th作者: dandruff 時(shí)間: 2025-3-30 17:12
Applications of Cardiac Extracellular Matrix in Tissue Engineering and Regenerative Medicine,ardiac regeneration as well as bottom-up and top-down approaches to ECM-based cardiac tissue engineering is discussed. Finally, lingering questions regarding the role of cECM in tissue engineering and regenerative medicine are offered as a catalyst for future research.作者: Parameter 時(shí)間: 2025-3-30 23:19
Whole Cardiac Tissue Bioscaffolds,he vascular conduits, injection into parenchyma, or a combination of perfusion and injection. Endothelial cells are often perfused through existing vessel conduits to provide an endothelial lining of the vasculature, with cardiomyocytes and other parenchymal cells injected into the myocardium of dec
